Inhibition of enzymic browning in cloudy apple juice with selected antibrowning agents

Golden Delicious apple juice was subjected to enzymic browning in the presence of the selected antibrowning agents: ascorbic acid, isoascorbic acid, L-cysteine, sorbic acid, benzoic acid, cinnamic acid and beta-cyclodextrin. The relative effectiveness of these antibrowning agents for inhibition of enzymic browning in apple juice was determined in terms of colour and enzyme activity measurements with respect to time for approximately one day storage period at 25 +/- 1 degreesC. The most effective agents were determined as L-cysteine, cinnamic acid and ascorbic acid. Response surf ace methodology was Used to evaluate the Potency of the L-cysteine, ascorbic acid and cinnamic acid combination for the control of enzymic browning. The ascorbic acid, L-cysteine and cinnamic acid combination provided better results than the individual compounds. The Optimum combination was determined as 0.49 mM ascorbic acid, 0.42 mM L-cysteine and 0.05 mM cinnamic acid in the cloudy apple juice stored for 2 h at 25 +/- 1 degreesC

The prevalence of Behcet's syndrome, familial Mediterranean fever, HLA-B51 and MEFV gene mutations among ethnic Armenians living in Istanbul, Turkey

Objectives: We investigated the prevalence of Behcet's syndrome (BS) among the ethnic Armenians in Istanbul using Familial Mediterranean Fever (FMF) as a comparator disease. We also studied HLA-B51 and MEFV mutations among a group of healthy Armenians and a non-Armenian population

Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery.

Applications of antibody de novo sequencing in the biopharmaceutical industry range from the discovery of new antibody drug candidates to identifying reagents for research and determining the primary structure of innovator products for biosimilar development. When murine, phage display, or patient-derived monoclonal antibodies against a target of interest are available, but the cDNA or the original cell line is not, de novo protein sequencing is required to humanize and recombinantly express these antibodies, followed by in vitro and in vivo testing for functional validation. Availability of fully automated software tools for monoclonal antibody de novo sequencing enables efficient and routine analysis. Here, we present a novel method to automatically de novo sequence antibodies using mass spectrometry and the Supernovo software. The robustness of the algorithm is demonstrated through a series of stress tests. Graphical Abstract ᅟ